239 related articles for article (PubMed ID: 20946881)
1. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
4. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
6. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
7. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
[TBL] [Abstract][Full Text] [Related]
8. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
9. [Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
Shang Z; Wang D; Xiao M; Wang J; Li TJ; Zhao YC; Li CR; Zhou JF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):607-12. PubMed ID: 23815907
[TBL] [Abstract][Full Text] [Related]
10. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
11. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
[TBL] [Abstract][Full Text] [Related]
13. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H
Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322
[TBL] [Abstract][Full Text] [Related]
14. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.
Chao HY; Jia ZX; Chen T; Lu XZ; Cen L; Xiao R; Jiang NK; Ying JH; Zhou M; Zhang R
Int J Lab Hematol; 2012 Oct; 34(5):502-9. PubMed ID: 22494415
[TBL] [Abstract][Full Text] [Related]
15. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Abbas S; Lugthart S; Kavelaars FG; Schelen A; Koenders JE; Zeilemaker A; van Putten WJ; Rijneveld AW; Löwenberg B; Valk PJ
Blood; 2010 Sep; 116(12):2122-6. PubMed ID: 20538800
[TBL] [Abstract][Full Text] [Related]
16. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
[TBL] [Abstract][Full Text] [Related]
17. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
[TBL] [Abstract][Full Text] [Related]
18. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
Middeke JM; Metzeler KH; Röllig C; Krämer M; Eckardt JN; Stasik S; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Brümmendorf TH; Naumann R; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Görlich D; Sauerland C; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Kaufmann M; Kunadt D; Wörmann B; Sockel K; von Bonin M; Herold T; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Baldus CD; Ehninger G; Schetelig J; Hiddemann W; Bornhäuser M; Stölzel F; Thiede C
Blood Adv; 2022 Mar; 6(5):1394-1405. PubMed ID: 34794176
[TBL] [Abstract][Full Text] [Related]
19. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
[TBL] [Abstract][Full Text] [Related]
20. Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.
Ashraf S; Noguera NI; Di Giandomenico J; Zaza S; Hasan SK; Lo-Coco F
Ann Hematol; 2013 Oct; 92(10):1319-23. PubMed ID: 23949315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
